
==== Front
J Nephrol
J Nephrol
Journal of Nephrology
1121-8428
1724-6059
Springer International Publishing Cham

38809361
1968
10.1007/s40620-024-01968-x
Original Article
Arterial stiffness and incident chronic kidney disease: a large population-based cohort study
http://orcid.org/0000-0003-3154-744X
Beros Angela 1
http://orcid.org/0000-0002-9722-139X
Sluyter John 1
http://orcid.org/0000-0001-5432-5271
Hughes Alun 2
http://orcid.org/0000-0003-2048-1019
Hametner Bernhard 3
http://orcid.org/0000-0002-5599-9689
Wassertheurer Siegfried 3
http://orcid.org/0000-0003-0013-2620
Scragg Robert r.scragg@auckland.ac.nz

1
1 https://ror.org/03b94tp07 grid.9654.e 0000 0004 0372 3343 School of Population Health, University of Auckland, Auckland, New Zealand
2 https://ror.org/02jx3x895 grid.83440.3b 0000 0001 2190 1201 Institute of Cardiovascular Sciences, University College London, London, UK
3 grid.4332.6 0000 0000 9799 7097 Center for Health and Bioresources, AIT Austrian Institute of Technology, Vienna, Austria
29 5 2024
29 5 2024
2024
37 5 12411250
21 2 2024
27 4 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Background/aims

Evidence from large population-based cohorts as to the association of arterial stiffness and incident chronic kidney disease (CKD) is mixed. This large population-based study aimed to investigate whether arterial stiffness, assessed oscillometrically, was associated with incident CKD.

Methods

The study population comprised 4838 participants from the Vitamin D Assessment (ViDA) Study without known CKD (mean ± SD age = 66 ± 8). Arterial stiffness was assessed from 5 April, 2011 to 6 November, 2012 by way of aortic pulse wave velocity, estimated carotid-femoral pulse wave velocity, and aortic pulse pressure. Incident CKD was determined by linkage to national hospital discharge registers. Cox proportional hazards regression was used to assess the risk of CKD in relation to chosen arterial stiffness measures over the continuum and quartiles of values.

Results

During a mean ± SD follow-up of 10.5 ± 0.4 years, 376 participants developed incident CKD. Following adjustment for potential confounders, aortic pulse wave velocity (hazard ratio (HR) per SD increase 1.69, 95% CI 1.45–1.97), estimated carotid-femoral pulse wave velocity (HR per SD increase 1.84, 95% CI 1.54–2.19), and aortic pulse pressure (HR per SD increase 1.37, 95% CI 1.22–1.53) were associated with the incidence of CKD. The risk of incident CKD was, compared to the first quartile, higher in the fourth quartile of aortic pulse wave velocity (HR 4.72, 95% CI 2.69–8.27; Ptrend < 0.001), estimated carotid-femoral pulse wave velocity (HR 4.28, 95% CI 2.45–7.50; Ptrend  < 0.001) and aortic pulse pressure (HR 2.71, 95% CI 1.88–3.91; Ptrend  < 0.001).

Conclusions

Arterial stiffness, as measured by aortic pulse wave velocity, estimated carotid-femoral pulse wave velocity, and aortic pulse pressure may be utilised in clinical practice to help identify people at risk of future CKD.

Trial registration

www.anzctr.org.au identifier:ACTRN12611000402943.

Graphical abstract

Supplementary Information

The online version contains supplementary material available at 10.1007/s40620-024-01968-x.

Keywords

Arterial stiffness
Cohort study
Chronic kidney disease
Pulse wave velocity
Pulse pressure
University of AucklandOpen Access funding enabled and organized by CAUL and its Member Institutions

issue-copyright-statement© Italian Society of Nephrology 2024
==== Body
pmcIntroduction

Chronic kidney disease (CKD) can lead to disability and is associated with premature death, particularly due to cardiovascular factors. A person is said to have CKD when their kidneys have had abnormal structure and function for > 3 months [1]. It was estimated that in 2017 11% of individuals worldwide (> 840 million people) were living with CKD [2]. Kidney function can decline by up to 90% before symptoms develop [3]. Chronic kidney disease is also largely irreversible, however, kidney function can often be preserved if the condition is properly managed. The prevalence of CKD increases with age and tends to be more common in ethnic minorities. In New Zealand, approximately 12% of the population may have CKD, with the highest prevalence estimated to be in indigenous Māori, Pacific (in New Zealand, predominantly people from the smaller Pacific nations of Samoa, Tonga and the Cook Islands) and people from South-Asia (the Indian Subcontinent)[4].

Arterial stiffness describes the rigidity of arterial walls and primarily refers to the stiffness of larger arteries and the aorta. Pulse wave velocity, a measure of the speed at which a forward pressure wave propagates in an artery is a measure of arterial stiffness, with higher measures indicating increased arterial rigidity [5]. The gold standard for evaluating aortic stiffness is the measurement of carotid-femoral pulse wave velocity [6]. Aortic pulse wave velocity can also be estimated from a blood pressure (BP) waveform obtained from a more peripheral artery, often the radial or brachial artery [6, 7]. Aortic pulse pressure is also recognised as a rough estimate of arterial stiffness [6].

Arterial stiffness may contribute to CKD incidence and progression due to increased pulsatile pressure on kidney microvasculature [5]. The evidence from large cohort studies assessing arterial stiffness and incident CKD, however, is inconclusive. Various studies, including the Framingham Heart Study [8] and the Health ABC Study [9] have found an association of arterial stiffness and incident CKD [10, 11]. Other such studies, however, have not observed a significant relationship [12, 13]. Four of these studies measured carotid-femoral pulse wave velocity by way of Doppler or tonometry [8, 9, 12, 13]. These techniques require specialized training, involve measurement from two places on the body whilst the participant lies supine, and may utilise bulky equipment. Two studies employed other measures of pulse wave velocity, namely brachial-ankle pulse wave velocity [10] and heart-ankle pulse wave velocity [11], which though easier to obtain than carotid-femoral pulse wave velocity still require the application of cuffs to all four limbs.

For arterial stiffness to be employed in clinical practice, it must be easy to measure, use a method that is acceptable to patients, and be cost-effective [14]. Technological advancements have led to the development of oscillometric devices which compute aortic pulse wave velocity using the measured brachial artery pressure waveform [6]; these devices are affordable, portable, and user-friendly as they mirror home BP devices and only require one cuff. Given that both age and mean arterial pressure influence pulse wave velocity, equations have also been formulated to estimate carotid-femoral pulse wave velocity [15].

We aimed to assess whether arterial stiffness, as assessed oscillometrically by aortic pulse wave velocity, estimated carotid-femoral pulse wave velocity, or aortic pulse pressure predicted incident CKD in a large population-based cohort, aged 50–84 years, in Auckland, New Zealand.

Materials and methods

Participants

We analysed data from the Vitamin D Assessment (ViDA) Study, a randomised controlled trial with the primary aim of evaluating the efficacy of vitamin D supplementation on reducing the incidence of cardiovascular disease (CVD)—no effect was observed [16]. Ethics approval was granted by the Ministry of Health (MoH) Multi-region Ethics committee (MEC/09/08/082). Participants provided written informed consent. Full study details have been published elsewhere [17].

Between 5 April, 2011, and 6 November, 2012, 5250 participants primarily enlisted from 55 family practices located in Auckland, New Zealand underwent a baseline assessment at the University of Auckland, with 5108 participants included in the final study.

We excluded from the analysis 203 participants for whom arterial stiffness measures were missing or excluded (due to poor quality waveforms with a signal-to-noise ratio of < 6 dB). We further excluded 67 participants identified as having CKD for the period between 1 April 2009 and each participant’s baseline interview, resulting in 4838 participants being included in the final analysis.

CKD and follow-up

The MoH allocates New Zealand residents a National Health Index number. This number was used to track deaths and hospital discharges [utilising the International Statistical Classification of Diseases and Health Related Problems, Tenth Revision (ICD-10) coding system]. Incident CKD was identified from the first occurrence of any hospital discharge record with the relevant ICD-10 code for the period beginning with each participant’s baseline interview up to 31 August, 2022. Such data were also used to exclude participants with CKD at baseline as identified from records for the period between 1 April, 2009 and each participant’s baseline interview, together with self-reported diabetic kidney disease at the baseline interview. The relevant ICD-10 codes are reported in Supplementary Information, Table S1.

Arterial stiffness

Central  BP measurements including heart rate, aortic pulse pressure and pulse waveform characteristics were obtained using a BP+ monitor (Uscom, Sydney, Australia), an oscillometric device with a correctly sized cuff placed on the upper left arm. The BP+ monitor has shown good intra-test and inter-test reliability when measuring central systolic BP [18]. The ARCSolver pulse wave algorithm (AIT Austrian Institute of Technology, GmbH, Vienna, Austria) was used to calculate aortic pulse wave velocity using the pressure waveform. This algorithm has been validated against aortic pulse wave velocity measured with an intra-aortic catheter [7]. Oscillometric devices can have inbuilt pulse wave algorithms, and hence are able to generate and save waveform parameters, including aortic pulse wave velocity, at the time of capture. Aortic mean arterial pressure was calculated as the area under the aortic pressure waveform (mmHg*seconds)/cardiac cycle duration (seconds) [19].

We implemented equations for estimated carotid-femoral pulse wave velocity based on those put forward by Greve et al. [20] and which are based on the Reference Values for Arterial Stiffness Collaboration equations [15]. These equations have predicted CVD events [20] and incident diabetes [21]. For participants with one or more CVD risk factors at baseline, estimated carotid-femoral pulse wave velocity was calculated as 4.62–0.13 × age + 0.0018 × age squared + 0.0006 × age × brachial mean arterial pressure (bMAP) + 0.0284 × bMAP. For participants with no CVD risk factors at baseline, estimated carotid-femoral pulse wave velocity was calculated as 9.587 − 0.402 × age + 0.004560 × age squared − 0.000026 × age squared × bMAP + 0.003176 × age × bMAP-0.018322 × bMAP. As defined in the development of these equations, bMAP was calculated as brachial diastolic BP + 0.4 × brachial pulse pressure. Cardiovascular disease risk factors, with criteria based on those used to develop the original equations were current tobacco smoking, hypertension (brachial systolic BP ≥ 140, or brachial diastolic BP ≥ 90, or as reported by a physician), dyslipidaemia (total cholesterol > 4.9 mmol/L, or HDL-C < 1 mmol/L, or total cholesterol/HDL-C ratio < 4, or as reported by a physician) and previous CVD events (heart attack, angina, heart failure, irregular heartbeat, transient ischaemic attack, stroke, carotid artery stenosis, or intermittent claudication as reported by a physician, or self-report of pacemaker).

Covariates

The baseline assessment included a questionnaire administered by trained interviewers adhering to a standardised protocol. Information was collected on socio-demographic factors (age, gender, self-reported ethnicity), lifestyle factors (divided into two categories: current and never/former for tobacco smoking and alcohol consumption, and > 2 h per week and ≤ 2 h per week for vigorous physical activity), medical history as reported by a physician (including diabetes, high cholesterol, hypertension and cardiovascular disease), current prescribed medications (diabetic, antihypertensives and lipid-lowering) and self-administered supplements, including vitamin D.

Participants were further identified as having diabetes or prediabetes if, between 1 April, 2009 and their baseline interview, they were identified through their National Health Index number as having an ICD-10 Code relating to diabetes or having received a prescription for diabetes medication. The relevant ICD-10 codes are reported in Supplementary Information, Table S1.

Socioeconomic status was estimated using a participant’s residential neighbourhood decile, as classified by the New Zealand Index of Deprivation 2013 (NZDep2013) (ranging from 1 to 10, with 1 representing the least deprived areas). Height was measured to the nearest 0.1 cm and weight to the nearest 0.1 kg. Body mass index (BMI) was calculated as weight (kg)/height (m2).

A non-fasting blood sample was collected and stored at a temperature of − 80 °C with samples subsequently analysed for total cholesterol, high-density lipoprotein cholesterol (HDL-C) and serum creatinine. Estimated glomerular filtration rate (eGFR) was calculated according to the Chronic Kidney Disease Epidemiology Collaboration Equation [22].

Statistical analysis

Data were analysed collectively and were also divided into aortic pulse wave velocity quartiles. The characteristics of the study population, by incident CKD status and by quartile of aortic pulse wave velocity were shown as mean ± SD or median (IQR) for continuous measures and frequency (%) for categorical measures.

The incidence rate of CKD for person-years was calculated as the number of incident cases/the total duration of follow-up (for each participant being the earlier of death date or 31 August, 2022). Comparisons of baseline characteristics, between participants who developed CKD and those who did not, were performed using t tests for continuous variables and Chi-square tests for categorical variables. We censored participants who died during the follow-up period.

Multivariable Cox regression models were used to evaluate the association between arterial stiffness as a continuous variable (measured by aortic pulse wave velocity, estimated carotid-femoral pulse wave velocity and aortic pulse pressure) and incident CKD. The analysis employed hazard ratios (HRs) with 95% CIs. We also computed HRs based on a SD increase of each arterial stiffness measure (sHR) and for quartiles of each arterial stiffness measure using the lowest level of each arterial stiffness measure as the reference group. Covariates were selected for inclusion in the models based on similar studies [9, 10, 13, 23–26].

Model 1 was adjusted for age, sex, ethnicity, BMI, eGFR, vitamin D treatment group and aortic mean arterial pressure. Model 2 comprised Model 1 plus lifestyle factors (tobacco smoking, alcohol drinking and vigorous physical activity), NZDep2013, history of CVD, diabetes/prediabetes, medications (diabetes, antihypertensives, lipid-lowering), total cholesterol, HDL-C and heart rate. Kaplan–Meier curves, stratified by quartiles of each arterial stiffness measure, were used to show the relationship between arterial stiffness and incident CKD.

SAS V9.4 (Cary, North Carolina, USA) was used for statistical analysis and all statistical tests were 2-sided.

Sensitivity analysis

To assess the influence of participants with undiagnosed CKD at baseline, we performed a sensitivity analysis where, in addition to any participants with identified CKD at baseline, we also excluded any other participants who had an eGFR < 60 ml/min per 1.73 m2, as one of the criteria for diagnosing CKD is having this reading for > 3 months [1].

Results

Baseline characteristics

Baseline characteristics of the participants (n = 4838) are presented in Table 1, overall, by incident CKD status and by quartile of baseline aortic pulse wave velocity. Mean age was 66 ± 8 years and 58% were men. The majority (84%) were European/other ethnicity, 5% identified as Māori, 6% as Pacific and 5% as South Asian. Mean ± SD arterial stiffness at baseline, as measured by aortic pulse wave velocity was 9.50 ± 1.75 m/s [median (IQR): 9.38 (2.47)], estimated carotid-femoral pulse wave velocity, 10.97 ± 1.72 m/s and aortic pulse pressure, 68 ± 16 mmHg. Of those participants, 4802 (99%) had ≥ 1 CVD risk factor.Table 1 Characteristics of participants without chronic kidney disease (CKD) at baseline in relation to the total sample, incident CKD status and quartile of baseline aortic pulse wave velocity (aPWV)

	Total sample	Incident CKD status	Quartile of aPWV, m/s	
	No CKD	CKD	P-Value	PWV < 8.20	8.20 ≤ PWV < 9.38	9.38 ≤ PWV < 10.67	PWV ≥ 10.67	
Number, n	4838	4462	376		1209	1210	1209	1210	
Age, y	66 ± 8	66 ± 8	71 ± 8	 < 0.001	57 ± 4	64 ± 4	69 ± 4	76 ± 5	
Men, %	2811 (58)	2545 (91)	266 (9)	 < 0.001	591 (21)	682 (24)	742 (27)	796 (28)	
Ethnicity, %				 < 0.001					
 European/other	4051 (84)	3776 (93)	275 (7)		808 (20)	1021 (25)	1092 (27)	1130 (28)	
 Māori	249 (5)	221 (89)	28 (11)		125 (50)	60 (24)	35 (14)	29 (12)	
 Pacific	301 (6)	251 (83)	50 (17)		147 (49)	74 (24)	54 (18)	26 (9)	
 South Asian	237 (5)	214 (90)	23 (10)		129 (54)	55 (23)	28 (12)	25 (11)	
Tobacco smoker, current, %	303 (6)	280 (92)	23 (8)	 < 0.001	132 (44)	77 (25)	58 (19)	36 (12)	
Alcohol drinker, current, %	4186 (87)	3884 (93)	302 (7)	 < 0.001	990 (24)	1051 (25)	1082 (26)	1063 (25)	
Vigorous physical activity, > 2 h per week, %	2190 (45)	2075 (95)	115 (5)	 < 0.001	602 (27)	620 (28)	515 (24)	453 (21)	
Body mass index, kg/m2 a	28 ± 5	28 ± 5	31 ± 6	 < 0.001	28 ± 6	29 ± 5	28 ± 5	28 ± 4	
Diabetes/prediabetes, current, %a	552 (11)	381 (69)	171 (31)	 < 0.001	123 (22)	133 (24)	150 (27)	146 (27)	
Cardiovascular disease, current/past, %	1124 (23)	957 (85)	167 (15)	 < 0.001	140 (13)	234 (21)	307 (27)	443 (39)	
NZDep2013, deciles 6-10a	1640 (34)	1473 (90)	167 (10)	 < 0.001	476 (29)	418 (25)	374 (23)	372 (23)	
Medications									
 Antihypertensives, %	1748 (36)	1498 (86)	250 (14)	 < 0.001	240 (14)	394 (22)	500 (29)	614 (35)	
 Diabetic medications, %	512 (11)	356 (70)	156 (30)	 < 0.001	126 (25)	119 (24)	141 (27)	126 (24)	
 Lipid lowering medications, %	1684 (35)	1473 (87)	211 (13)	 < 0.001	277 (16)	420 (25)	480 (29)	507 (30)	
Vitamin D supplementation, %	2422 (50)	2242 (93)	180 (7)	0.39	608 (25)	609 (25)	599 (25)	606 (25)	
eGFR, ml/min per 1.73 m2	72 ± 12	73 ± 11	61 ± 14	 < 0.001	77 ± 11	73 ± 11	71 ± 11	66 ± 11	
Total cholesterol, mmol/L	4.87 ± 1.09	4.92 ± 1.08	4.21 ± 1.06	 < 0.001	5.03 ± 1.09	4.93 ± 1.09	4.84 ± 1.07	4.66 ± 1.09	
HDL-C, mmol/L	1.42 ± 0.43	1.43 ± 0.42	1.24 ± 0.41	 < 0.001	1.42 ± 0.42	1.42 ± 0.43	1.42 ± 0.42	1.41 ± 0.43	
aPWV, m/s, median (IQR)	9.38 (2.47)	9.30 (2.41)	10.51 (2.63)	 < 0.001	7.46 (0.89)	8.80 (0.61)	9.95 (0.65)	11.70 (1.34)	
ecfPWV, m/s	10.97 ± 1.72	10.89 ± 1.71	11.91 ± 1.67	 < 0.001	8.96 ± 0.78	10.32 ± 0.59	11.43 ± 0.61	13.18 ± 0.98	
Systolic BP, aortic, mmHg	140 ± 19	140 ± 19	145 ± 19	 < 0.001	127 ± 14	136 ± 15	144 ± 16	155 ± 20	
Diastolic BP, aortic, mmHg	72 ± 6	72 ± 6	72 ± 6	0.91	71 ± 6	72 ± 6	73 ± 6	74 ± 7	
Pulse pressure, aortic, mmHg	68 ± 16	68 ± 15	73 ± 17	 < 0.001	56 ± 11	64 ± 11	71 ± 12	81 ± 16	
Mean arterial pressure, aortic, mmHg	100 ± 12	100 ± 12	99 ± 12	0.70	95 ± 10	98 ± 11	101 ± 12	105 ± 12	
Heart rate, bpm	63 ± 10	63 ± 10	65 ± 11	0.002	65 ± 10	63 ± 10	63 ± 10	62 ± 10	
Data shown as mean ± SD for continuous measures and frequency (column % for total sample; row % for incident CKD status and quartile of aPWV) for categorical measures. BP, blood pressure; ecfPWV, estimated carotid-femoral PWV; PWV, Pulse wave velocity; HDL-C high-density lipoprotein cholesterol; NZDep2013, New Zealand Index of Deprivation 2013

Incident CKD

The mean ± SD length of follow up was 10.5 ± 0.4 years, during which 376 participants developed CKD, with a higher cumulative incidence for Māori (11%), Pacific (17%) and South Asian (10%), compared to European/other (7%) (Table 1).

Table 2 shows associations between measures of arterial stiffness and risk of incident CKD both overall, and by quartile of each arterial stiffness measure. The incidence of CKD overall was 7.38 per 1000 person years.Table 2 Incidence and hazard ratios of chronic kidney disease (CKD) in relation to the total sample and quartiles of baseline arterial stiffness measures

Participants, nc	Total samplea	Total sampleb	Quartile of arterial stiffness—hazard ratios (95% CI)	P for trend	
4838		1209	1210	1209	1210		
aPWV, m/s			PWV < 8.20	8.20 ≤ PWV < 9.38	9.38 ≤ PWV < 10.67	PWV ≥ 10.67		
CKD incidence, n (n per 1000 person years)	376 (7.38)		37 (2.85)	63 (4.95)	102 (8.09)	174 (13.78)		
 Model 1	1.35 (1.24–1.48)	1.69 (1.45–1.97)	Reference	1.79 (1.15–2.79)	3.07 (1.83–5.15)	4.72 (2.69–8.27)	 < 0.001	
 Model 2	1.31 (1.19–1.44)	1.60 (1.36–1.90)	Reference	1.71 (1.08–2.72)	2.68 (1.56–4.61)	4.19 (2.31–7.59)	 < 0.001	
 ecfPWV, m/s			PWV < 9.71	9.71 ≤ PWV < 10.87	10.87 ≤ PWV < 12.11	PWV ≥ 12.11		
CKD incidence, n (n per 1000 person years)	376 (7.38)		38 (2.93)	69 (5.43)	102 (8.07)	167 (13.23)		
 Model 1	1.42 (1.29–1.58)	1.84 (1.54–2.19)	Reference	1.72 (1.11–2.68)	2.48 (1.50–4.12)	4.28 (2.45–7.50)	 < 0.001	
 Model 2	1.37 (1.23–1.53)	1.72 (1.43–2.08)	Reference	1.64 (1.04–2.59)	2.24 (1.33–3.78)	3.89 (2.17–6.96)	 < 0.001	
 aPP, mmHg			PP < 57	57 ≤ PP < 66	66 ≤ PP < 77	PP ≥ 77		
CKD incidence, n (n per 1000 person years)	376 (7.38)		55 (4.29)	76 (5.96)	112 (8.83)	133 (10.50)		
 Model 1	1.02 (1.01–1.03)	1.37 (1.22–1.53)	Reference	1.36 (0.96–1.94)	1.99 (1.41–2.81)	2.71 (1.88–3.91)	 < 0.001	
 Model 2	1.03 (1.02–1.04)	1.51 (1.32–1.72)	Reference	1.65 (1.14–2.38)	2.59 (1.78–3.78)	3.82 (2.52–5.79)	 < 0.001	
aPWV aortic pulse wave velocity, ecfPWV estimated carotid-femoral pulse wave velocity, aPP aortic pulse pressure

Model 1 is adjusted for age, sex, ethnicity, body mass index, vitamin D treatment group, aortic mean arterial pressure and eGFR measured by creatinine

Model 2 is adjusted for the variables in Model 1 plus lifestyle factors (tobacco smoking, alcohol drinking, vigorous physical activity), medications (antihypertensives, diabetes, lipid-lowering), diabetes/prediabetes, history of cardiovascular disease, total cholesterol, high-density lipoprotein cholesterol, New Zealand Index of Deprivation 2013, heart rate

aData for model 1 and model 2 are hazard ratios (95% confidence intervals) for measures of arterial stiffness as a continuous variable

bData are hazard ratios (95% confidence intervals) for measures of arterial stiffness as a continuous variable and are standardised (per 1 SD)

cParticipant numbers for model 2 total 4745 due to missing data

In model 1, each SD increase in aortic pulse wave velocity was associated with a 69% greater risk of incident CKD (sHR, 1.69, 95% CI 1.45–1.97), estimated carotid-femoral pulse wave velocity was associated with an 84% greater risk of incident CKD (sHR 1.84, 95% CI 1.54–2.19) and aortic pulse pressure with a 37% greater risk of incident CKD (sHR 1.37, 95% CI 1.22–1.53) after adjusting for age, sex, ethnicity, BMI, vitamin D treatment group, aortic mean arterial pressure and eGFR. The sHRs remained significant in model 2, which also adjusted for lifestyle factors, medications, diabetes/prediabetes, history of CVD, NZDep2013, heart rate, total cholesterol and HDL-C.

Figure 1 shows that the cumulative incidence of CKD increased with each increasing arterial stiffness quartile. In model 1, the risk of incident CKD was, compared to the first quartile, higher in the fourth quartile of aortic pulse wave velocity (HR 4.72, 95% CI 2.69–8.27), estimated carotid-femoral pulse wave velocity (HR 4.28, 95% CI 2.45–7.50) and aortic pulse pressure (HR 2.71, 95% CI 1.88–3.91). These associations remained significant when we adjusted for the additional covariates in model 2. There was a significant positive trend for the quartiles of all measures of arterial stiffness for both model 1 and model 2.Fig. 1 Cumulative incidence of chronic kidney disease (CKD) by arterial stiffness quartiles (1–4); PWV pulse wave velocity, PP pulse pressure

Applying aortic pulse wave velocity in model 1, aortic mean arterial pressure (HR 0.98, 95% CI 0.97–0.99), sex (HR for men 2.74, 95% CI 2.17–3.46), ethnicity [European/other, reference; Māori (HR 2.45, 95% CI 1.63–3.68); Pacific (HR 2.67, 95% CI 1.91–3.75); South Asian (HR 3.76, 95% CI 2.43–5.83)], BMI (HR 1.09, 95% CI 1.07–1.11) and eGFR (HR 0.92, 95% CI 0.91–0.93) were all associated with an increased risk of incident CKD (Supplementary Information, Table S2). These associations remained significant when aortic pulse wave velocity was substituted for estimated carotid-femoral pulse wave velocity or aortic pulse pressure. After adjusting for the additional covariates in model 2, all associations, for all models, apart from South Asian for aortic pulse wave velocity and aortic pulse pressure, remained significant. In addition, in model 2, tobacco smoking, vigorous physical activity, NZDep2013, CVD, diabetes and medications (antihypertensives, diabetic) were also associated with incident CKD.

Sensitivity analysis

We undertook sensitivity analysis where participants with a baseline eGFR < 60 ml/min per 1.73 m2 (n = 759) were excluded from the analysis (Supplementary Information, Table S3). For both models, when arterial stiffness was measured by aortic pulse wave velocity and estimated carotid-femoral pulse wave velocity, the risk of incident CKD was slightly higher than for when people with a baseline eGFR < 60 ml/min per 1.73 m2 were also included (for model 1: sHR 1.74, 95% CI 1.40–2.17; sHR 1.89, 95% CI 1.47–2.44, respectively) and was substantively the same for aortic pulse pressure. There was also a significant positive trend for the quartiles of all arterial stiffness measures for both models.

Discussion

In a large population-based study, with a follow-up of 10.5 years, higher arterial stiffness, as measured by aortic pulse wave velocity, estimated carotid-femoral pulse wave velocity and aortic pulse pressure, was associated with an increased risk of developing CKD. Further, our results showed that as the quartile of each arterial stiffness measure increased so did the risk of incident CKD.

To our knowledge, this is the first large population study that has investigated the association of arterial stiffness with incident CKD using oscillometrically-measured arterial stiffness. Our study findings are consistent with other large-scale population studies that have found positive associations between arterial stiffness and incident CKD. Those studies which employed carotid-femoral pulse wave velocity include the Framingham Heart Study [8] (sHR 1.17, 95% CI 1.01–1.35) and the Health ABC Study [9] (incident rate ratio per doubling of carotid-femoral pulse wave velocity 1.42, 95% CI 1.12–1.81). Positive associations were also found where arterial stiffness was measured utilising brachial-ankle pulse wave velocity [10] (odds ratio per m/s higher pulse wave velocity 1.36, 95% CI 1.09–1.70) and heart-ankle pulse wave velocity [11] (sHR 1.12, 95% CI 1.05–1.18).

In contrast, no relationship was found between carotid-femoral pulse wave velocity and incident CKD in the Rotterdam Study [13] (relative risk per SD increase in pulse wave velocity 1.05, 95% CI 0.99–1.31) or in the AGE-RS Study [12] (odds ratio per m/s higher pulse wave velocity 1.16, 95% CI 0.84–1.61). However, the Rotterdam Study [13] may have been subject to selection bias having pulse wave velocity data for only 2665 out of 3666 participants, while the AGE-RS Study [12] suffered from attrition bias after losing 310 out of 940 participants to follow-up. These studies, aside from the Health ABC Study [9], had mainly ethnically homogeneous populations and were unable to report results by ethnicity.

Māori and Pacific in this study had a higher risk of incident CKD than their European/other counterparts. In addition to having the highest prevalences of socio-economic deprivation in New Zealand, these people also have the highest prevalences of obesity, and hence diabetes and CVD [27]. This in turn is a large driver of the high CKD prevalence in this population. Māori and Pacific, however, still had higher risk of CKD in our analysis when we controlled for NZDep2013, BMI, physical activity, diabetes and CVD risk factors. Although diabetic nephropathy is the major cause of CKD in Māori and Pacific people, there is increasing evidence that there may be a familial or ethnic predisposition to CKD that is not due to diabetes or hypertension [28, 29].

The kidney is a high blood flow organ with low resistance vascular beds. Increased arterial stiffness exposes the smaller arteries of the kidney to increased pulsatile stress, possibly resulting in damage to endothelial and vascular smooth muscle cells [5]. Capillaries of the glomerulus, which are situated between afferent and efferent arterioles, may be particularly susceptible to damage, as the efferent arterioles have greater resistance than the afferent arterioles which leads to high pulsatile pressure in the glomerulus [5].

Our study has certain strengths. First, we had a long follow-up period. Second, as our study also included Māori, Pacific peoples and South Asian ethnicities, our results were generalizable to those populations and not just Europeans. Third, as outcomes were ascertained from hospital discharge registers, there was no loss to follow-up of participants.

This study has some limitations. First, as we did not clinically assess CKD, we may not have excluded all people with CKD from our initial study cohort. We did, however, control for eGFR. Further, in population studies it is widely accepted that CKD can be established with an eGFR < 60 ml/min per 1.73 m2 [30]. When we removed people at baseline who fit this definition of CKD, our conclusions remained unaltered. Second, as we had to rely on hospitalisations to identify CKD, not all people who developed CKD would have been identified. Third, as the study is observational, we cannot be completely sure of causality.

To combat the global prevalence of CKD, and as people with this condition are generally asymptomatic, new approaches to the identification and prevention of CKD are needed. We found that arterial stiffness, as measured by aortic pulse wave velocity, estimated carotid-femoral pulse wave velocity and aortic pulse pressure, was positively associated with future CKD development. Arterial stiffness, which can be easily and accurately measured, could be used as a tool in clinical practice (as part of routine BP measurement and diabetes monitoring) to help identify people at risk of CKD.

Supplementary Information

Below is the link to the electronic supplementary material.Supplementary file1 (PDF 152 KB)

Acknowledgements

We thank all the research staff at the University of Auckland for help conducting the ViDA study and the New Zealand Ministry of Health for providing the hospitalisation and prescription dispensing data. We also thank the study participants and their family physicians for facilitating their participation in the ViDA Study.

Funding

Open Access funding enabled and organized by CAUL and its Member Institutions. Angela Beros was supported by a University of Auckland Doctoral Scholarship.

Data availability

Participants gave consent for data to be available only to the study research team

Declarations

Conflict of interest

There are no conflicts of interest to declare.

Ethical approval

The study was conducted in accordance with standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Human and animal rights

This study involving human participants was approved by the New Zealand Ministry of Health Multi-region Ethics committee (MEC/09/08/082).

Informed consent

Informed consent was obtained from all individual participants prior to their enrolment in the study.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Levey AS Eckardt KU Dorman NM Christiansen SL Hoorn EJ Ingelfinger JR Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference Kidney Int 2020 97 6 1117 1129 32409237
Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR et al (2020) Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. Kidney Int 97(6):1117–1129. 10.1016/j.kint.2020.02.01032409237
2. Jager KJ Kovesdy C Langham R Rosenberg M Jha V Zoccali C A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases Kidney Int 2019 96 5 1048 1050 31582227
Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C (2019) A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases. Kidney Int 96(5):1048–1050. 10.1016/j.kint.2019.07.01231582227
3. Kidney Health Australia Chronic kidney disease (CKD) management in primary care 2020 4 Melbourne Kidney Health Australia
Kidney Health Australia (2020) Chronic kidney disease (CKD) management in primary care, 4th edn. Kidney Health Australia, Melbourne
4. Ministry of Health Managing chronic kidney disease in primary care: a national consensus statement 2015 Wellington Ministry of Health
Ministry of Health (2015) Managing chronic kidney disease in primary care: a national consensus statement. Ministry of Health, Wellington
5. Chirinos JA Segers P Hughes T Townsend R Large-artery stiffness in health and disease: JACC state-of-the-art review J Am Coll Cardiol 2019 74 9 1237 1263 31466622
Chirinos JA, Segers P, Hughes T, Townsend R (2019) Large-artery stiffness in health and disease: JACC state-of-the-art review. J Am Coll Cardiol 74(9):1237–1263. 10.1016/j.jacc.2019.07.01231466622
6. Laurent S Cockcroft J Van Bortel L Boutouyrie P Giannattasio C Hayoz D Expert consensus document on arterial stiffness: methodological issues and clinical applications Eur Heart J 2006 27 21 2588 2605 17000623
Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D et al (2006) Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 27(21):2588–2605. 10.1093/eurheartj/ehl25417000623
7. Hametner B Wassertheurer S Kropf J Mayer C Eber B Weber T Oscillometric estimation of aortic pulse wave velocity: Comparison with intra-aortic catheter measurements Blood Press Monit 2013 18 3 173 176 23571229
Hametner B, Wassertheurer S, Kropf J, Mayer C, Eber B, Weber T (2013) Oscillometric estimation of aortic pulse wave velocity: Comparison with intra-aortic catheter measurements. Blood Press Monit 18(3):173–176. 10.1097/MBP.0b013e328361416823571229
8. Vasan RS Pan S Xanthakis V Beiser A Larson MG Seshadri S Mitchell GF Arterial stiffness and long-term risk of health outcomes: the Framingham Heart Study Hypertension 2022 79 5 1045 1056 35168368
Vasan RS, Pan S, Xanthakis V, Beiser A, Larson MG, Seshadri S, Mitchell GF (2022) Arterial stiffness and long-term risk of health outcomes: the Framingham Heart Study. Hypertension 79(5):1045–1056. 10.1016/hypertensionaha.121.1877635168368
9. Madero M Peralta C Katz R Canada R Fried L Najjar S Association of arterial rigidity with incident kidney disease and kidney function decline: the Health ABC Study Clin J Am Soc Nephrol 2013 8 3 424 433 23271800
Madero M, Peralta C, Katz R, Canada R, Fried L, Najjar S et al (2013) Association of arterial rigidity with incident kidney disease and kidney function decline: the Health ABC Study. Clin J Am Soc Nephrol 8(3):424–433. 10.2215/cjn.0790081223271800
10. Tomiyama H Tanaka H Hashimoto H Matsumoto C Odaira M Yamada J Arterial stiffness and declines in individuals with normal renal function/early chronic kidney disease Atherosclerosis 2010 212 1 345 350 20594557
Tomiyama H, Tanaka H, Hashimoto H, Matsumoto C, Odaira M, Yamada J et al (2010) Arterial stiffness and declines in individuals with normal renal function/early chronic kidney disease. Atherosclerosis 212(1):345–350. 10.1016/j.atherosclerosis.2010.05.03320594557
11. Nagayama D Fujishiro K Miyoshi T Horinaka S Suzuki K Shimizu K Saiki A Shirai K Predictive ability of arterial stiffness parameters for renal function decline: a retrospective cohort study comparing cardio-ankle vascular index, pulse wave velocity and cardio-ankle vascular index0 J Hypertens 2022 40 7 1294 1302 35703238
Nagayama D, Fujishiro K, Miyoshi T, Horinaka S, Suzuki K, Shimizu K, Saiki A, Shirai K (2022) Predictive ability of arterial stiffness parameters for renal function decline: a retrospective cohort study comparing cardio-ankle vascular index, pulse wave velocity and cardio-ankle vascular index0. J Hypertens 40(7):1294–1302. 10.1097/hjh.000000000000313735703238
12. Huang N Foster MC Mitchell GF Andresdottir MB Eiriksdottir G Gudmundsdottir H Aortic stiffness and change in glomerular filtration rate and albuminuria in older people Nephrol Dial Transplant 2017 32 4 677 684 27190377
Huang N, Foster MC, Mitchell GF, Andresdottir MB, Eiriksdottir G, Gudmundsdottir H et al (2017) Aortic stiffness and change in glomerular filtration rate and albuminuria in older people. Nephrol Dial Transplant 32(4):677–684. 10.1093/ndt/gfw05027190377
13. Sedaghat S Mattace-Raso FU Hoorn EJ Uitterlinden AG Hofman A Ikram MA Franco OH Dehghan A Arterial stiffness and decline in kidney function Clin J Am Soc Nephrol 2015 10 12 2190 2197 26563380
Sedaghat S, Mattace-Raso FU, Hoorn EJ, Uitterlinden AG, Hofman A, Ikram MA, Franco OH, Dehghan A (2015) Arterial stiffness and decline in kidney function. Clin J Am Soc Nephrol 10(12):2190–2197. 10.2215/cjn.0300031526563380
14. Hlatky MA Greenland P Arnett DK Ballantyne CM Criqui MH Elkind MS Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association Circulation 2009 119 17 2408 2416 19364974
Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS et al (2009) Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119(17):2408–2416. 10.1161/circulationaha.109.19227819364974
15. The Reference Values for Arterial Stiffness’ Collaboration Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’ Eur Heart J 2010 31 19 2338 2350 20530030
The Reference Values for Arterial Stiffness’ Collaboration (2010) Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values.’ Eur Heart J 31(19):2338–2350. 10.1093/eurheartj/ehq16520530030
16. Scragg R Stewart AW Waayer D Lawes CMM Toop L Sluyter J Murphy J Khaw KT Camargo CA Jr Effect of monthly high-dose vitamin D supplementation on cardiovascular disease in the Vitamin D Assessment Study: a randomized clinical trial JAMA Cardiol 2017 2 6 608 616 28384800
Scragg R, Stewart AW, Waayer D, Lawes CMM, Toop L, Sluyter J, Murphy J, Khaw KT, Camargo CA Jr (2017) Effect of monthly high-dose vitamin D supplementation on cardiovascular disease in the Vitamin D Assessment Study: a randomized clinical trial. JAMA Cardiol 2(6):608–616. 10.1001/jamacardio.2017.017528384800
17. Scragg R Waayer D Stewart AW Lawes CMM Toop L Murphy J Khaw KT Camargo CA Jr The Vitamin D Assessment (ViDA) Study: design of a randomized controlled trial of vitamin D supplementation for the prevention of cardiovascular disease, acute respiratory infection, falls and non-vertebral fractures J Steroid Biochem Mol Biol 2016 164 318 325 26365555
Scragg R, Waayer D, Stewart AW, Lawes CMM, Toop L, Murphy J, Khaw KT, Camargo CA Jr (2016) The Vitamin D Assessment (ViDA) Study: design of a randomized controlled trial of vitamin D supplementation for the prevention of cardiovascular disease, acute respiratory infection, falls and non-vertebral fractures. J Steroid Biochem Mol Biol 164:318–325. 10.1016/j.jsbmb.2015.09.01026365555
18. Climie RE Schultz MG Nikolic SB Ahuja KD Fell JW Sharman JE Validity and reliability of central blood pressure estimated by upper arm oscillometric cuff pressure Am J Hypertens 2012 25 4 414 420 22223041
Climie RE, Schultz MG, Nikolic SB, Ahuja KD, Fell JW, Sharman JE (2012) Validity and reliability of central blood pressure estimated by upper arm oscillometric cuff pressure. Am J Hypertens 25(4):414–420. 10.1038/ajh.2011.23822223041
19. Tien LYH Morgan WH Cringle SJ Yu DY Optimal calculation of mean pressure from pulse pressure Am J Hypertens 2023 36 6 297 305 36945835
Tien LYH, Morgan WH, Cringle SJ, Yu DY (2023) Optimal calculation of mean pressure from pulse pressure. Am J Hypertens 36(6):297–305. 10.1093/ajh/hpad02636945835
20. Greve SV Blicher MK Kruger R Sehestedt T Gram-Kampmann E Rasmussen S Estimated carotid-femoral pulse wave velocity has similar predictive value as measured carotid-femoral pulse wave velocity J Hypertens 2016 34 7 1279 1289 27088638
Greve SV, Blicher MK, Kruger R, Sehestedt T, Gram-Kampmann E, Rasmussen S et al (2016) Estimated carotid-femoral pulse wave velocity has similar predictive value as measured carotid-femoral pulse wave velocity. J Hypertens 34(7):1279–1289. 10.1097/hjh.000000000000093527088638
21. Bao W Chen C Chen C Zhang X Miao H Zhao X Huang S Li C Association between estimated pulse wave velocity and risk of diabetes: a large sample size cohort study Nutr Metab Cardiovasc Dis 2023 33 9 1716 1724 37414667
Bao W, Chen C, Chen C, Zhang X, Miao H, Zhao X, Huang S, Li C (2023) Association between estimated pulse wave velocity and risk of diabetes: a large sample size cohort study. Nutr Metab Cardiovasc Dis 33(9):1716–1724. 10.1016/j.numecd.2023.05.03237414667
22. Inker LA Schmid CH Tighiouart H Eckfeldt JH Feldman HI Greene T Estimating glomerular filtration rate from serum creatinine and cystatin C N Engl J Med 2012 367 1 20 29 22762315
Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T et al (2012) Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 367(1):20–29. 10.1056/nejmoa111424822762315
23. Gottsäter M Östling G Persson M Engström G Melander O Nilsson PM Non-hemodynamic predictors of arterial stiffness after 17 years of follow-up: the Malmö Diet and Cancer study J Hypertens 2015 33 5 957 965 25634451
Gottsäter M, Östling G, Persson M, Engström G, Melander O, Nilsson PM (2015) Non-hemodynamic predictors of arterial stiffness after 17 years of follow-up: the Malmö Diet and Cancer study. J Hypertens 33(5):957–965. 10.1097/hjh.000000000000052025634451
24. Li J Cui L Zhang X Hou J Wang A Wu Y Longitudinal study of brachial-ankle pulse wave velocity and change in estimated glomerular filtration rate among Chinese adults Kidney Blood Press Res 2021 46 3 266 274 33902026
Li J, Cui L, Zhang X, Hou J, Wang A, Wu Y et al (2021) Longitudinal study of brachial-ankle pulse wave velocity and change in estimated glomerular filtration rate among Chinese adults. Kidney Blood Press Res 46(3):266–274. 10.1159/00051061133902026
25. Liu JJ Liu S Lee J Gurung RL Yiamunaa M Ang K Aortic pulse wave velocity, central pulse pressure, augmentation index and chronic kidney disease progression in individuals with type 2 diabetes: a 3 year prospective study BMC Nephrol 2020 21 1 359 32819303
Liu JJ, Liu S, Lee J, Gurung RL, Yiamunaa M, Ang K et al (2020) Aortic pulse wave velocity, central pulse pressure, augmentation index and chronic kidney disease progression in individuals with type 2 diabetes: a 3 year prospective study. BMC Nephrol 21(1):359. 10.1186/s12882-020-02024-z32819303
26. Upadhyay A Hwang SJ Mitchell GF Vasan RS Vita JA Stantchev PI Arterial stiffness in mild-to-moderate CKD J Am Soc Nephrol 2009 20 9 2044 2053 19608701
Upadhyay A, Hwang SJ, Mitchell GF, Vasan RS, Vita JA, Stantchev PI et al (2009) Arterial stiffness in mild-to-moderate CKD. J Am Soc Nephrol 20(9):2044–2053. 10.1681/asn.200901007419608701
27. Ministry of Health Annual update of key results 2015/16: New Zealand Health Survey 2016 Wellington Ministry of Health
Ministry of Health (2016) Annual update of key results 2015/16: New Zealand Health Survey. Ministry of Health, Wellington
28. Thompson CF Simmons D Collins JF Cecil A Predisposition to nephropathy in Polynesians is associated with family history of renal disease, not diabetes mellitus Diabet Med 2001 18 1 40 46 11168340
Thompson CF, Simmons D, Collins JF, Cecil A (2001) Predisposition to nephropathy in Polynesians is associated with family history of renal disease, not diabetes mellitus. Diabet Med 18(1):40–46. 10.1046/j.1464-5491.2001.00406.x11168340
29. Walker RJ Tafunai M Krishnan A Chronic kidney disease in New Zealand Māori and Pacific people Semin Nephrol 2019 39 3 297 299 31054629
Walker RJ, Tafunai M, Krishnan A (2019) Chronic kidney disease in New Zealand Māori and Pacific people. Semin Nephrol 39(3):297–299. 10.1016/j.semnephrol.2019.03.00131054629
30. Bash LD Coresh J Köttgen A Parekh RS Fulop T Wang Y Astor BC Defining incident chronic kidney disease in the research setting: the ARIC Study Am J Epidemiol 2009 170 4 414 424 19535543
Bash LD, Coresh J, Köttgen A, Parekh RS, Fulop T, Wang Y, Astor BC (2009) Defining incident chronic kidney disease in the research setting: the ARIC Study. Am J Epidemiol 170(4):414–424. 10.1093/aje/kwp15119535543
